Stocks

What to watch: SPARC faces Abraxis’ complaint in the US

| Updated on August 21, 2019 Published on August 21, 2019

 

Sun Pharma Advanced Research Company has said that Abraxis Biosciences LLC has filed a complaint against the company in the US District Court (New Jersey).

 It has alleged that SPARC’s filing of the New Drug Application for Taclantis injection (Paclitaxel Injection Concentrate for Suspension) is an act of infringement of the orange book listed patents for Abraxane.

“SPARC believes that this lawsuit is without merit and will vigorously defend against these allegations.”

Published on August 21, 2019
This article is closed for comments.
Please Email the Editor